Alnylam Pharmaceuticals Inc (A1LN34)
BOV
Fin d'année 31 Décembre 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Return on Assets (%) | -30.959 | -30.138 | -42.666 | -44.641 | -29.585 | -24.192 | -31.466 | -11.937 |
Return on Equity (%) | -37.54 | -36.542 | -49.635 | -64.664 | -69.923 | -106.307 | -526.144 | 232.399 |
Return on Invested Capital (%) | -52.899 | -42.702 | -53.884 | -70.058 | -65.765 | -61.157 | -82.171 | -40.288 |
Operating Margin (%) | -869.628 | -545.949 | -1015.478 | -402.846 | -156.457 | -83.991 | -93.6 | -17.081 |
Net Profit Margin (%) | -869.628 | -545.949 | -1016.576 | -403.238 | -174.145 | -101.011 | -109.036 | -24.079 |
Book Value Per Share | 10.708 | 17.723 | 12.868 | 12.824 | 8.729 | 4.894 | -1.277 | -1.758 |
Earnings Per Share | -4.772 | -4.925 | -7.526 | -7.898 | -7.372 | -7.096 | -9.128 | -3.508 |
Cash Per Share | 2.253 | 6.475 | 4.153 | 4.877 | 4.265 | 6.823 | 6.991 | 6.476 |
Working Capital Per Share | 6.285 | 16.259 | 10.093 | 12.152 | 17.432 | 17.581 | 15.528 | 16.056 |
Operating Profit Per Share | 0.549 | 0.902 | 0.723 | 1.735 | 3.563 | 6.255 | 7.368 | 12.526 |
EBIT Per Share | -4.772 | -4.925 | -7.518 | -7.891 | -7.349 | -7.09 | -9.094 | -3.455 |
EBITDA Per Share | -4.772 | -4.925 | -7.518 | -7.891 | -7.349 | -7.09 | -9.094 | -3.455 |
Free Cash Flow Per Share | -4.132 | -3.999 | -6.399 | -6.797 | -7.027 | -6.856 | -8.905 | -3.443 |
Fin d'année 31 Décembre 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Actions en circulation | 85,94M | 99,67M | 101,18M | 112,19M | 116,43M | 120,18M | 123,93M | N/A |
Fin d'année 31 Décembre 2023 | Déc 2022 | Mar 2023 | Juin 2023 | Sept 2023 | Déc 2023 | Mar 2024 | Juin 2024 | Sept 2024 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Actions en circulation | 123,93M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Assets (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Equity (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Invested Capital (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Margin (%) | N/A | -44.914 | N/A | N/A | N/A | -5.732 | N/A | N/A |
Net Profit Margin (%) | N/A | -54.528 | N/A | N/A | N/A | -13.338 | N/A | N/A |
Sales Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Earnings Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Cash Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Working Capital Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Profit Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBIT Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBITDA Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Free Cash Flow Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Capitalisation boursière | 9,22B |
Ratio cours/bénéfice | -69,34 |
Ratio prix/ventes | 16,7 |
Ratio prix/liquidités | 37,56 |
Ratio prix/valeur comptable | -138,35 |
Rendement de dividende | - |
Actions en circulation | 125,49M |
Volume moyen (1 semaine) | 183 |
Volume moyen (1 mois) | 242 |
Variation sur 52 semaines | 54,11% |
Plus haut sur 52 semaines | 85,44 |
Plus bas sur 52 semaines | 36,23 |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales